Gamida Cell Ltd. announced that two oral presentations and a poster presentation highlighting Gamida Cell's investigational product candidates, omidubicel and GDA-201, were shared at the 2023 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT), and the Center for International Blood and Marrow Transplant Research (CIBMTR). The meetings took place February 15-19 virtually and in person in Orlando, Florida.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 USD | +2.41% | 0.00% | -95.88% |
23/05 | Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
10/04 | Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-95.88% | 26.19L | |
+9.83% | 12TCr | |
+10.80% | 11TCr | |
-10.84% | 2.34TCr | |
-1.69% | 2.21TCr | |
-10.23% | 1.83TCr | |
-41.92% | 1.66TCr | |
-15.11% | 1.6TCr | |
+6.62% | 1.4TCr | |
+17.53% | 1.17TCr |
- Stock Market
- Equities
- GMDA Stock
- News Gamida Cell Ltd.
- Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR